Shoushtari, A. N., Middleton, M. R., Hamid, O., Meier, F., Bauer, T., Salama, A. K. S., … Evans, T. R. J. (2023). 1107P BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma. In Annals of Oncology (Vol. 34, pp. S667–S668). Elsevier BV. https://doi.org/10.1016/j.annonc.2023.09.2241

Shoushtari, A. N., M. R. Middleton, O. Hamid, F. Meier, T. Bauer, A. K. S. Salama, J. M. Kirkwood, et al. “1107P BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma.” In Annals of Oncology, 34:S667–68. Elsevier BV, 2023. https://doi.org/10.1016/j.annonc.2023.09.2241.

Shoushtari AN, Middleton MR, Hamid O, Meier F, Bauer T, Salama AKS, et al. 1107P BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma. In: Annals of Oncology. Elsevier BV; 2023. p. S667–8.

Shoushtari, A. N., et al. “1107P BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma.” Annals of Oncology, vol. 34, Elsevier BV, 2023, pp. S667–68. Crossref, doi:10.1016/j.annonc.2023.09.2241.

Shoushtari AN, Middleton MR, Hamid O, Meier F, Bauer T, Salama AKS, Kirkwood JM, Ascierto PA, Lorigan P, Mauch C, Orloff M, Edukulla R, Goodall H, Hassel JC, Evans TRJ. 1107P BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma. Annals of Oncology. Elsevier BV; 2023. p. S667–S668.